FindTrial
Sign In

Phase II clinical study of R435 (bevacizumab) in combination with paclitaxel in patients with inoperable metastatic breast cancer

Phase II clinical study of R435 (bevacizumab) in combination with paclitaxel in patients with inoperable metastatic breast cancer

Status
Unknown
Phases
Phase 2
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCT2080220385
Enrollment
Unknown
Registered
2007-04-26
Start date
2007-04-26
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Inoperable metastatic breast cancer

Interventions

investigational material(s) Generic name etc : R435 (Bevacizumab)|paclitaxel INN of investigational material : Therapeutic category code : 429 Other antitumor agents Dosage and Administration for Inv

Sponsors

Chugai Pharmaceutical Co., Ltd.
Lead Sponsor

Eligibility

Sex/Gender
Female

Inclusion criteria

Inclusion criteria: - at least 20 years old and obtained a written informed consent - Advanced breast cancer (Stage IV) or Inoperable metastatic breast cancer - HER2 negative - At least one measurable lesion based on RECIST criteria - No previous chemotherapy for metastatic breast cancer

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Primary endpoints: Safety, Progression-free survival (PFS) Secondary endpoints: Tumor response (Response rate, duration of response, Time to response), Overall survival (OS), Time to treatment failure (TTF)—

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026